Comparison
DSIP vs. MGF (Mechano Growth Factor)
Two peptides side-by-side — identity, evidence base, legal status and known adverse events.
Identity
Category
Research other
Growth
CAS no.
62568-57-4
12-Aminosäuren-C-terminales E-Domänen-Peptid (Sequenz nicht standardisiert)
Molecular weight
848.81 g/mol
2867.2 g/mol
Half-life
0.1 h
0.1 h
Sequence
Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-GluYQPPSTNKNTKSQRRKGSTFEERKMechanism of action
DSIP
DSIP was described in 1977 by the Schoenenberger-Monnier group in Basel as a blood-borne substance reported to induce EEG changes similar to delta sleep in animal models. The exact mechanism remains undefined to this day: no defined receptor, proposed modulation of opioid, GABAergic and glutamatergic systems. Most mechanistic findings stem from preclinical studies of the 1980s and 1990s and were later subjected to contested replication attempts.
MGF (Mechano Growth Factor)
The IGF-1 gene produces multiple isoforms by alternative splicing. IGF-1Ec is upregulated after mechanical muscle loading; the C-terminal E-domain is cleaved from the mature IGF-1 protein and appears to have independent effects on satellite cells. The exact receptor binding of the E-domain is not established; a classical IGF-1R effect is unlikely since mature IGF-1 is responsible. In cell-culture studies, stimulation of myoblast proliferation and differentiation has been observed.
Evidence base
Highest evidence
Human trial
Animal model
Studies
4
4
of which in humans
1
0
Effects recorded
3
3
Open conflicts
1
0
Documented adverse events
1
1